HURA
TuHURA Biosciences, Inc./NVCompany Information
- Company Name
- TuHURA Biosciences, Inc./NV
- CIK
- CIK0001498382
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- HURA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- HURA
SEC filing data through
Insider Sentiment
- Last purchase
- 2022-02-15
- Last sale
- —
- Shares purchased (TTM)
- 124,809
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 8,798,507
- Shares outstanding
- 63,963,513
- Ownership
- 13.76%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -13.36%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Series A Preferred Stock | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Series C Preferred Stock | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Related Party | - | - | - | - | - | - | - | 0 | - | -0 | -0 | 0 | ||||||
| Cash And Cash Equivalents At Carrying Value | 1 | 6 | 4 | 3 | 9 | 6 | 5 | 3 | 5 | 6 | 1 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 2 | 7 | 5 | 4 | 13 | 14 | 6 | 3 | 6 | 7 | 1 | 1 | ||||||
| Stockholders Equity Note Subscriptions Receivable | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 1 | ||||||
| Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Goodwill | 11 | 11 | 11 | 14 | 14 | - | - | - | - | - | - | - | ||||||
| Deferred Finance Costs Noncurrent Net | 7 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets | 32 | 30 | 27 | 26 | 35 | 15 | 6 | 4 | 6 | 7 | 2 | 1 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 9 | 6 | 6 | 9 | 15 | 5 | 2 | 2 | 2 | 1 | 2 | 3 | ||||||
| Accounts Payable And Accrued Liabilities Current | 4 | 6 | 6 | 5 | 12 | 5 | 2 | 2 | 2 | 1 | 2 | 3 | ||||||
| Other Liabilities Current | - | - | - | - | - | - | - | - | 0 | - | - | - | ||||||
| Notes Payable Current | - | - | - | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Asset Acquisition Contingent Consideration Liability Current | - | - | - | 3 | 3 | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Other Liabilities Noncurrent | - | - | - | 0 | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Deferred Income Tax Liabilities Net | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 13 | 7 | 6 | 9 | 15 | 5 | 2 | 2 | 2 | 2 | 2 | 4 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 19 | 23 | 21 | 17 | 19 | 10 | 4 | -3 | 4 | -6 | -0 | -2 | ||||||
| Additional Paid In Capital Common Stock | 176 | 172 | 162 | 151 | 146 | 130 | 153 | 163 | 153 | 153 | 145 | 142 | ||||||
| Retained Earnings Accumulated Deficit | -158 | -149 | -141 | -134 | -127 | -118 | -160 | -162 | -160 | -158 | -156 | -155 | ||||||
| Liabilities And Stockholders Equity | 32 | 30 | 27 | 26 | 35 | 15 | 6 | 4 | 6 | 7 | 2 | 1 | ||||||
| Preferred Stock Shares Authorized | - | - | 5 | - | - | - | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | ||||||
| Common Stock Shares Issued | 64 | 64 | 59 | 51 | 50 | 44 | 55 | 2 | 55 | 55 | 10 | 2 | ||||||
| Shares Outstanding | 64 | 64 | 59 | 51 | 50 | 44 | 12 | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTuHURA Biosciences, Inc./NV (HURA) — SEC Financial Statements & Analysis
TuHURA Biosciences, Inc./NV (HURA) is a pharmaceutical preparations company, incorporated in NV. TuHURA Biosciences, Inc./NV trades on Nasdaq as: HURA. TuHURA Biosciences, Inc./NV (HURA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, TuHURA Biosciences, Inc./NV carries a market cap of $149.67M, a P/E ratio of -4.66x, a P/B ratio of 8.09x, an enterprise value of $148.68M, and an EV/EBITDA multiple of -4.56x. On profitability, it posts a Return on Equity (ROE) of -169.43%, a Return on Assets (ROA) of -96.88%, and a Return on Invested Capital (ROIC) of -226.22%. Per share, it reports EPS of $-0.50, diluted EPS of $-0.50, free cash flow per share of $-0.59, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 52.47% year-over-year and EPS growth of 6.21% year-over-year. On the balance sheet, it maintains a current ratio of 0.18x, a quick ratio of 0.18x, working capital of $-7.60M, a debt-to-equity ratio of 0.72x, a debt ratio of 0.42, an interest coverage ratio of -63.77x, free cash flow of $-37.94M (TTM), and net debt of $-995.98K. Figures sourced from SEC EDGAR.
- Market Cap
- $149.67M
- P/E TTM
- -4.66x
- EPS TTM
- $-0.50
- P/B TTM
- 8.09x
- ROE TTM
- -169.43%
- ROA TTM
- -96.88%
- Debt To Equity
- 0.72x
- Free Cash Flow TTM
- $-37.94M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is TuHURA Biosciences, Inc./NV in?
TuHURA Biosciences, Inc./NV (HURA) operates in the Pharmaceutical Preparations industry.
What exchange does HURA trade on?
TuHURA Biosciences, Inc./NV (HURA) trades on the Nasdaq.
Where is TuHURA Biosciences, Inc./NV incorporated?
TuHURA Biosciences, Inc./NV is incorporated in NV.
When was TuHURA Biosciences, Inc./NV (HURA)'s most recent SEC filing?
TuHURA Biosciences, Inc./NV (HURA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is HURA's market cap?
TuHURA Biosciences, Inc./NV (HURA) has a market capitalization of $149.67M as of 2026-06-30.
What is HURA's EPS (earnings per share)?
TuHURA Biosciences, Inc./NV (HURA)'s trailing twelve month EPS is $-0.50 as of 2026-06-30.
What is HURA's ROE (return on equity)?
TuHURA Biosciences, Inc./NV (HURA)'s trailing twelve month Return on Equity (ROE) is -169.43% as of 2026-06-30.
What is HURA's ROA (return on assets)?
TuHURA Biosciences, Inc./NV (HURA)'s trailing twelve month Return on Assets (ROA) is -96.88% as of 2026-06-30.
What is HURA's ROIC (return on invested capital)?
TuHURA Biosciences, Inc./NV (HURA)'s trailing twelve month Return on Invested Capital (ROIC) is -226.22% as of 2026-06-30.
What is HURA's EV/EBITDA?
TuHURA Biosciences, Inc./NV (HURA)'s trailing twelve month EV/EBITDA is -4.56x as of 2026-06-30.